DE60221238D1 - Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung - Google Patents

Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung

Info

Publication number
DE60221238D1
DE60221238D1 DE60221238T DE60221238T DE60221238D1 DE 60221238 D1 DE60221238 D1 DE 60221238D1 DE 60221238 T DE60221238 T DE 60221238T DE 60221238 T DE60221238 T DE 60221238T DE 60221238 D1 DE60221238 D1 DE 60221238D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
manufacturing low
low dosed
dosed pharmaceutical
manufacturing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60221238T
Other languages
English (en)
Other versions
DE60221238T2 (de
Inventor
Daniel S Gierer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60221238D1 publication Critical patent/DE60221238D1/de
Publication of DE60221238T2 publication Critical patent/DE60221238T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60221238T 2001-05-01 2002-03-13 Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung Expired - Fee Related DE60221238T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28784101P 2001-05-01 2001-05-01
US287841P 2001-05-01
PCT/IB2002/000766 WO2002087546A2 (en) 2001-05-01 2002-03-13 Method for manufacturing a low dose pharmaceutical composition

Publications (2)

Publication Number Publication Date
DE60221238D1 true DE60221238D1 (de) 2007-08-30
DE60221238T2 DE60221238T2 (de) 2007-10-31

Family

ID=23104578

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60221238T Expired - Fee Related DE60221238T2 (de) 2001-05-01 2002-03-13 Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung

Country Status (44)

Country Link
US (2) US7037530B2 (de)
EP (1) EP1383482B1 (de)
JP (1) JP2004531537A (de)
KR (1) KR100568380B1 (de)
CN (1) CN1240375C (de)
AP (1) AP2003002900A0 (de)
AR (1) AR033288A1 (de)
AT (1) ATE367152T1 (de)
AU (1) AU2002236166B2 (de)
BG (1) BG108297A (de)
BR (1) BR0209283A (de)
CA (1) CA2445519C (de)
CZ (1) CZ20032959A3 (de)
DE (1) DE60221238T2 (de)
DK (1) DK1383482T3 (de)
DO (1) DOP2002000389A (de)
EA (1) EA005949B1 (de)
EC (1) ECSP034826A (de)
EE (1) EE200300537A (de)
ES (1) ES2286226T3 (de)
GE (1) GEP20053654B (de)
GT (1) GT200200078A (de)
HK (1) HK1065705A1 (de)
HR (1) HRP20030858A2 (de)
HU (1) HUP0401391A3 (de)
IL (1) IL158390A0 (de)
IS (1) IS6985A (de)
MA (1) MA27017A1 (de)
MX (1) MXPA03009391A (de)
NO (1) NO20034709L (de)
NZ (1) NZ528886A (de)
OA (1) OA12596A (de)
PA (1) PA8544401A1 (de)
PE (1) PE20021137A1 (de)
PL (1) PL366453A1 (de)
PT (1) PT1383482E (de)
SK (1) SK286536B6 (de)
TN (1) TNSN03106A1 (de)
TW (1) TWI264311B (de)
UA (1) UA75135C2 (de)
UY (1) UY27277A1 (de)
WO (1) WO2002087546A2 (de)
YU (1) YU81503A (de)
ZA (1) ZA200307819B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009259A (es) 2002-03-28 2005-01-25 Pfizer Prod Inc Lasofoxifeno racemico purificado y d-tartrato de lasofoxifeno purificado y un metodo para la purificacion efectiva del lasofoxifeno racemico.
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
EP2023745A1 (de) * 2006-05-17 2009-02-18 WM. Wrigley Jr., Company Verfahren zur herstellung eines lebensmittelprodukts
FI20070521L (fi) 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
FI20080351A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
US20100179110A1 (en) * 2006-12-20 2010-07-15 Mostafa Akbarieh Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
US20080181972A1 (en) * 2007-01-29 2008-07-31 Valentina Amico Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
ES2603617T3 (es) 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica
KR101784647B1 (ko) 2008-05-02 2017-10-11 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
EP2291233B1 (de) * 2008-05-09 2019-09-04 Atacama Labs Oy Verfahren für trockene granulation
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
EA029996B1 (ru) 2008-06-06 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Капсулярная лекарственная форма, содержащая суспензионную композицию производного индолинона
ES2520990T3 (es) * 2009-01-29 2014-11-12 Ucb Pharma, S.A. Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina
CN104083328B (zh) * 2009-01-29 2017-04-12 Ucb生物制药私人有限公司 包含2‑氧代‑1‑吡咯烷衍生物的药物组合物
US20140350945A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America System and Method for Validation of Pharmaceutical Composition Formulations
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
CN106176649B (zh) * 2016-08-31 2020-04-17 北京斯利安药业有限公司 叶酸vb12片及其制备方法
MX2019009777A (es) * 2017-02-17 2019-10-14 Massachusetts Inst Technology Sistemas y metodos para la fabricacion de tabletas, que incluyen tabletas farmaceuticas.
CZ309820B6 (cs) * 2021-04-23 2023-11-08 Pro.Med.Cs Praha A.S. Způsob přípravy pevné lékové formy obsahující kompozici s nízkým obsahem účinné látky

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725555A (en) * 1967-08-01 1973-04-03 Ciba Geigy Corp Bactericidal compositions and method of killing bacteria using bis-(phenoxyphenyl) carbonates
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
GB1570993A (en) * 1976-05-21 1980-07-09 Fisons Ltd Pharmaceutical tablet formulation
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5107331A (en) * 1989-03-07 1992-04-21 The Color Group Method and apparatus for producing half-tone separations at the same screen angle
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5976570A (en) * 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
JPH10204082A (ja) * 1996-10-25 1998-08-04 Eli Lilly & Co 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ[b]チオフェン化合物
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
EP0889056B1 (de) * 1997-07-01 2006-04-12 Pfizer Products Inc. Verfahren zur Herstellung von einem Cyclodextrin
US6300367B1 (en) * 1999-04-20 2001-10-09 Protein Technologies International, Inc. Composition for and method of preventing or treating breast cancer
US6555551B1 (en) * 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos

Also Published As

Publication number Publication date
MA27017A1 (fr) 2004-12-20
ES2286226T3 (es) 2007-12-01
ZA200307819B (en) 2004-10-07
HK1065705A1 (en) 2005-03-04
ATE367152T1 (de) 2007-08-15
CA2445519C (en) 2009-01-20
EA200301040A1 (ru) 2004-04-29
MXPA03009391A (es) 2004-01-29
IS6985A (is) 2003-10-09
CN1240375C (zh) 2006-02-08
DE60221238T2 (de) 2007-10-31
HUP0401391A3 (en) 2009-06-29
BR0209283A (pt) 2004-07-13
GEP20053654B (en) 2005-11-10
CA2445519A1 (en) 2002-11-07
AR033288A1 (es) 2003-12-10
US7037530B2 (en) 2006-05-02
HRP20030858A2 (en) 2005-08-31
TNSN03106A1 (fr) 2005-12-23
US20060093667A1 (en) 2006-05-04
AP2003002900A0 (en) 2003-12-31
CN1531423A (zh) 2004-09-22
NO20034709D0 (no) 2003-10-21
OA12596A (en) 2006-06-08
PE20021137A1 (es) 2002-12-14
DOP2002000389A (es) 2002-11-30
IL158390A0 (en) 2004-05-12
WO2002087546A3 (en) 2003-02-13
BG108297A (bg) 2005-07-29
EP1383482A2 (de) 2004-01-28
NZ528886A (en) 2005-04-29
SK13552003A3 (sk) 2004-09-08
UA75135C2 (en) 2006-03-15
CZ20032959A3 (cs) 2004-01-14
GT200200078A (es) 2003-01-31
PL366453A1 (en) 2005-02-07
KR20040015226A (ko) 2004-02-18
SK286536B6 (sk) 2008-12-05
PT1383482E (pt) 2007-09-20
US7176221B2 (en) 2007-02-13
JP2004531537A (ja) 2004-10-14
AU2002236166B2 (en) 2006-12-07
US20030004182A1 (en) 2003-01-02
HUP0401391A2 (hu) 2004-12-28
EE200300537A (et) 2004-04-15
WO2002087546A2 (en) 2002-11-07
TWI264311B (en) 2006-10-21
YU81503A (sh) 2006-08-17
DK1383482T3 (da) 2007-10-29
NO20034709L (no) 2003-10-31
EP1383482B1 (de) 2007-07-18
EA005949B1 (ru) 2005-08-25
PA8544401A1 (es) 2003-07-28
ECSP034826A (es) 2004-02-26
KR100568380B1 (ko) 2006-04-05
UY27277A1 (es) 2002-11-29

Similar Documents

Publication Publication Date Title
DE60221238D1 (de) Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung
FI20011478A (fi) Farmaseuttinen koostumus
NO20033384L (no) Farmasoytisk formulering
IS6986A (is) Lyfjasamsetning í vökvaformi
NO20033785D0 (no) Farmasöytisk formulering
BR0210619A (pt) composição
IS7051A (is) Lyfjasamsetningar
NO20035627D0 (no) Farmasöytisk formulering
FI20022128A (fi) Farmaseuttinen koostumus
ITTO20020789A1 (it) Formulazione solida
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60234592D1 (de) Wässrige zusammensetzung
DE50214751D1 (de) Dosiervorrichtung
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
NO20024880L (no) Sammensetning inneholdende fosfat
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DK1429753T3 (da) Farmaceutisk sammensætning omfattende gamma-butyrobetain
DE60223671D1 (de) Dosierpumpe
DE10107261B4 (de) Pharmazeutische Zusammensetzung
DE50213685D1 (de) Dosiervorrichtung
NO20041236L (no) Farmasoytisk formulering
FI5468U1 (fi) Farmaseuttinen koostumus
SE0100199D0 (sv) New formulation
SE0100847D0 (sv) Novel pharmaceutical composition
DK1307264T3 (da) Hidtil ukendt farmaceutisk præparat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee